Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Luye Closes $269 Million Acquisition of Swiss Pharma's Patch Business

publication date: Dec 2, 2016
Luye Pharma has closed its $269 million acquisition of Acino's transdermal drug delivery business, which it announced earlier this year. Acino, a Swiss company, offers high-margin, difficult-to-make transdermal patch products for niche markets that include CNS, pain and hormone indications. Luye positioned the transaction as a two-way street: it will bring Acino's products and technology to the China market, while it also uses Acino's expertise with non-China markets to export its China drug portfolio. More details....

Stock Symbol: (HK: 2186)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital